Literature DB >> 31479364

Spending On Postacute Care After Hospitalization In Commercial Insurance And Medicare Around Age Sixty-Five.

Scott E Regenbogen1, Anne H Cain-Nielsen2, John D Syrjamaki3, Lena M Chen4, Edward C Norton5.   

Abstract

Postacute care costs are the primary determinant of episode spending around hospitalization. Yet there is little evidence that greater spending on postacute care improves readmission rates or functional recovery. Recent Medicare payment reform evaluations have suggested that postacute care spending is responsive to episode-based incentives. However, it remains unknown whether Medicare payment policies are responsible for excess postacute care spending, compared with that of commercial payers. In a population-based, statewide collaborative of Michigan hospitals, we used regression discontinuity design among propensity-weighted, age-adjusted cohorts to compare postacute care spending between patients with commercial insurance and those with Medicare around age sixty-five. Spending was 68-230 percent greater among fee-for-service Medicare beneficiaries than among similar commercially insured people across varied medical and surgical conditions. Despite greater spending, there were no differences in readmission rates. These findings suggest that postacute care utilization is highly sensitive to payer influence, and there may be an opportunity for additional savings in Medicare without sacrificing quality.

Entities:  

Keywords:  bundled payments; episode-based reimbursement; insurance design; post-acute care; regression-discontinuity; reimbursement reform

Mesh:

Year:  2019        PMID: 31479364     DOI: 10.1377/hlthaff.2018.05445

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  1 in total

1.  Lessons from Medicare's Bundled Payments for Care Improvement initiative for postacute care.

Authors:  Caroline P Thirukumaran
Journal:  J Am Geriatr Soc       Date:  2021-09-12       Impact factor: 5.562

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.